Author details

Full Name

Hie-Won Hann

Affiliation

ORCID

Career Start Year

1971

Papers

127

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37174929	Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study.		2023
37905449	Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96â¿¿weeks.		2023
38062093	Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.		2023
36818365	The Role of Host in the Spectrum of Outcomes in Family Clusters of Hepatitis Infection: From Asymptomatic to Hepatocellular Carcinoma.		2023
37307947	Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA.		2023
35046521	Urine DNA biomarkers for hepatocellular carcinoma screening.	British Journal of Cancer	2022
35460726	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.	J Hepatol	2022
35458505	Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level.	Viruses	2022
35445803	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.	Hepatol Commun	2022
35697332	Safety and efficacy of vebicorvir administered with entecavir in treatment-naÃ¯ve patients with chronic hepatitis B virus infection.	J Hepatol	2022
35409275	Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress.	International Journal of Molecular Sciences	2022
34558837	Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected Patients.	Hepatology Communications	2021
34451963	Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series.	Vaccines	2021
31306800	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.	Clin Gastroenterol Hepatol	2020
30705719	Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure.	World Journal of Hepatology	2019
29677098	Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.		2018
30127954	Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection.	Oncology Letters	2018
29479728	An expert consensus for the management of chronic hepatitis B in Asian Americans.	Aliment Pharmacol Ther	2018
27545497	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.	J Hepatol	2017
28334112	Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients.	Carcinogenesis	2017
28795155	Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.	Hepatoma Research	2017
28054479	Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression.	Minerva Gastroenterologica e Dietologica	2017
26712941	The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.	Cancer Prev Res (Phila)	2016
27063412	Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection.	Scientific Reports	2016
27325221	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.	Am J Gastroenterol	2016
24995497	Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.	Journal of Gastroenterology and Hepatology (Australia)	2015
25588520	Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study.	Digestive Diseases and Sciences	2015
25826452	Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?	Expert Opinion on Drug Safety	2015
25000955	Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy.	Minerva Gastroenterologica e Dietologica	2014
24355416	HBV-related health behaviors in a socio-cultural context: perspectives from Khmers and Koreans.	Appl Nurs Res	2014
24368224	Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.	Gastroenterology	2014
24574709	Then and now: the progress in hepatitis B treatment over the past 20 years.		2014
24519810	A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation.	Cancer Medicine	2014
25013391	Advances in the management of hepatitis B virus infection.	Gastroenterology and Hepatology	2014
23261143	Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma.	Journal of Vascular and Interventional Radiology	2013
23112834	Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.	PLoS ONE	2012
22436980	Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort.	European Journal of Cancer	2012
22471856	Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis.	Liver International	2012
22444598	Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection.	European Journal of Cancer	2012
23057710	Correlates of hepatitis B virus health-related behaviors of Korean Americans: a situation-specific nursing theory.	J Nurs Scholarsh	2012
21935699	The management of chronic hepatitis B in Asian Americans.	Dig Dis Sci	2011
21484148	Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.	Hepatol Int	2011
21347651	Recognition and management of HBV infection in a social context.	J Cancer Educ	2011
20473872	Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated.	International Journal of Cancer	2011
21694465	Analysis of GP73 in patients with HCC as a function of anti-cancer treatment.	Cancer Biomarkers	2010
20698726	Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.	Expert Opinion on Pharmacotherapy	2010
20648601	Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009).	Journal of Medical Virology	2010
19065670	Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.	Hepatology	2009
18363895	Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.	Alimentary Pharmacology and Therapeutics	2008
19669319	A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance.	Hepatology International	2008